News/ News/ R&D GBT heads to FDA with sickle cell drug voxelotor Phil Taylor Global Blood Therapeutics, sickle cell, voxelotor 0 Comment Global Blood Therapeutics (GBT) has persuaded the FDA to accept biomarker data from a phase III trial of Share X GBT heads to FDA with sickle cell drug voxelotor https://pharmaphorum.com/news/gbt-heads-to-fda-with-sickle-cell-drug-voxelotor/
